11:51 AM ET
8-K
Capital Raise
Kairos Pharma Capital Raise
Kairos Pharma, Ltd. entered into a third amendment to its existing equity line of credit (ELOC) purchase agreement with Helena Global Investment Opportunities I Ltd. The amendment extends the company's option to use the ELOC for an additional year until December 31, 2028, and follows previous amendments that adjusted the purchase price to 97% of VWAP and shortened the pricing period.
- Counterparty
- Helena Global Investment Opportunities I Ltd.
- Term
- through Dec 2028